canine cancer Archives - Page 2 of 2

Canine Cancer Continuum | Part 2: The Connection Between Canine and Human Cancer

We’re halfway through a series exploring canine cancer. Last week, we discussed the prevalence of dog cancer, and today we will explore the connection between it and human cancer. Human cancer research is extensive. Almost anyone I encounter has either battled cancer themselves or has journeyed that path with someone close to them. Many people are surprised to learn that one in four dogs are diagnosed with cancer and that it’s the leading cause of death in canines. ELIAS Animal Health applies the advancements in human immunotherapy to dogs. They’re good models. From a scientific perspective, we are able to gather data more quickly than in human research because dogs have a shorter lifespan and cancer progresses more quickly in them. From a “we love our furry friends” perspective, we want to bring needed therapies into the veterinary marketplace that help people. ELIAS Cancer Therapies Are Being Simultaneously Developed for Humans [...]

By Tammie Wahaus|2023-01-24T19:57:18-06:00January 27th, 2022|Categories: Blog|Tags: cancer immunotherapy, canine cancer, oncolytic virus|0 Comments

Canine Cancer Continuum | Part 1: The Prevalence of Dog Cancer

We’re embarking on a 3-part series that explores dog cancer, how our research and progress can be applied to humans, what immunotherapy is, and why it can be so effective. “Cancer is the leading cause of death in dogs and as a rank order, higher than people…” - Dr. Doug Thamm Dogs live in the same environments as humans, exposed to the carcinogens that their owners are. It’s not surprising, then, that one in four dogs is diagnosed with cancer, and it’s the leading cause of death in pets beyond middle age (Veterinary Cancer Society). Dogs experience cancer at rates that are comparable to or exceed those in humans. Canine cancer has primarily been treated the same way for decades - with chemotherapy. Dr. Carolyn Henry, Dean of the University of Missouri College of Veterinary Medicine, has said she is “frustrated by the fact that we don’t see many new therapies coming [...]

By Tammie Wahaus|2022-05-30T12:01:26-06:00January 20th, 2022|Categories: Blog|Tags: cancer immunotherapy, canine cancer, ECI|0 Comments

ELIAS Animal Health and BodeVet announce new collaboration

Olathe, Kan., June 6, 2019 – ELIAS Animal Health, a clinical stage development company advancing novel treatments for cancer in companion animals, and BodeVet, a Maryland-based company focused on the development of novel blood products for use in veterinary transfusion and regenerative medicine, have announced a joint effort to significantly expand the availability of ELIAS’ ECI® treatment for canine cancer via the mobile apheresis capabilities of BodeVet. Apheresis is a processing procedure that separates blood into different components and, in this case, yields the T cells critical to the ELIAS treatment protocol. Currently, there are twelve locations offering apheresis for pets. BodeVet offers a mobile service that will enable veterinary oncologists in most major cities in the United States to incorporate ECI® into their specialty hospital portfolio of oncology services, expanding beyond chemotherapy and radiation. Working together, ELIAS and BodeVet are committed to promoting animal health and welfare by developing [...]

By Jessica Wiley|2020-02-26T15:07:39-06:00June 6th, 2019|Categories: Press Releases|Tags: autologous prescription product, bodevet, cancer immunotherapy, canine cancer|0 Comments

ELIAS Animal Health featured on Worldwide Business with kathy ireland®

Olathe, Kan., May 15, 2019 – ELIAS Animal Health, a Kansas City company dedicated to improving the treatment options for companion animals diagnosed with cancer, will be featured on Worldwide Business with kathy ireland®. Distributed internationally as sponsored content, you can view a highlight video below. The full interview will air on the following channels: Americas: Fox Business Network May 19, 2019, 5:30 p.m. EST Europe & Africa: Bloomberg EMEA Saturday, May 18, 2019, 7:30 p.m. GMT Asia: Bloomberg Asia Sunday, May 19, 2019, 10:30 a.m. D.F. and 3:00 p.m. HKT

By Jessica Wiley|2019-06-11T21:23:44-06:00May 16th, 2019|Categories: Press Releases|Tags: cancer immunotherapy, canine cancer|0 Comments

University announces advancement in canine cancer treatment

The University of Missouri recently shared progress on their work in helping advance ELIAS Animal Health’s treatment for bone cancer in dogs. The canine immunotherapy treatment is now available at MU, as well as at other universities and specialty hospitals across the country. Dr. Jeff Bryan, director of the MU's Comparative Oncology and Epigenetics Laboratory and principal investigator of the clinical trial, said of the treatment, “It’s the first time that dogs with osteosarcoma have experienced prolonged survival without receiving chemotherapy, which is really exciting.” Read the full announcement.

By Jessica Wiley|2020-02-26T15:08:42-06:00March 3rd, 2019|Categories: News|Tags: cancer immunotherapy, canine cancer, canine osteosarcoma, university of missouri|0 Comments

ELIAS Animal Health Announces Positive Results in Treatment of Osteosarcoma in Dogs

Olathe, Kan., Oct. 25, 2018 – ELIAS Animal Health, a clinical stage development company advancing novel treatments for cancer in companion animals, announced results from its canine osteosarcoma immunotherapy trial at the 2018 Veterinary Cancer Society (VCS) Annual Conference. The study evaluating ELIAS’ Autologous Prescription Product, known as ELIAS Cancer Immunotherapy (ECI®) resulted in a median survival time (MST) of 415 days in animals completing therapy – compared to historical treatment outcomes associated with surgery alone (134 days). These results will be included in the ELIAS submission to USDA-CVB during the fourth quarter. ELIAS intends to initiate a larger field safety and efficacy study in early 2019. “We are very encouraged by our osteosarcoma clinical trial results as we move towards commercialization of ECI® for the veterinary community, while continuing to explore our platform technology in other cancers such as lymphoma,” said Noe Reyes, D.V.M., ELIAS medical director. The trial [...]

By Jessica Wiley|2022-08-04T18:47:03-06:00October 25th, 2018|Categories: Press Releases|Tags: canine cancer, canine osteosarcoma, results|0 Comments

ELIAS autologous prescription product exceeds expectations for trial safety and efficacy

Olathe, Kan., July 31, 2018 – ELIAS Animal Health, a clinical stage development company advancing novel treatments for cancer in companion animals, shared promising preliminary canine osteosarcoma results for its cancer immunotherapy at the 2018 American College of Veterinary Internal Medicine (ACVIM) Forum in June. The study indicated its new ELIAS autologous cancer vaccine, featuring a patented combination of vaccine and T cell infusion approach, demonstrated impressive survival times and minimal side effects. This cancer immunotherapeutic is being distributed as an experimental product under 9 CFR 103.3 to veterinarians treating dogs diagnosed with cancer. Efficacy and safety have not been established. The results were presented by Brian Flesner, D.V.M., Dipl. ACVIM-Oncology, University of Missouri, and highlight continued progress within the immunotherapy arena for the treatment of canine cancer. One in four dogs will be impacted by cancer in their lifetimes and cancer is the No. 1 cause of death in [...]

By Jessica Wiley|2020-02-26T15:09:41-06:00July 31st, 2018|Categories: Press Releases|Tags: autologous prescription product, canine cancer|0 Comments

ELIAS Animal Health Cancer Immunotherapy selected for state of the art presentation at VCS Mid‐Year Conference

Olathe, Kan., Feb. 12, 2018 – ELIAS Animal Health, a clinical stage development company advancing novel treatments for cancer in companion animals, has been selected by the Veterinary Cancer Society (VCS) for a “State of the Art” presentation at its Mid‐Year Conference in Anchorage, Alaska, March 10‐13. The mid‐year conference is focused on immunotherapy. Brenda Phillips, D.V.M., Dipl. ACVIM (Oncology) will present “T cell‐mediated immunotherapy for common canine cancers” during the state of the art presentation on Sunday, March 11. Dr. Phillips is a board‐certified specialist in medical oncology, practicing with Veterinary Specialty Hospital in San Diego, Calif. The clinical process, ongoing trials, management and experiences of this treatment being developed specifically for veterinary use in dogs will be discussed during the 30‐minute presentation. More data from the study is expected to be presented at the ACVIM Forum in June. ELIAS Animal Health has applied for conditional licensure of its [...]

By Jessica Wiley|2020-02-26T15:10:20-06:00February 12th, 2018|Categories: Press Releases|Tags: canine cancer|0 Comments